DDInter281 DDInter131
Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Canakinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Canakinumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Canakinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alprazolam
Canakinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tuberculin purified protein derivative
Canakinumab {u} may lead to a major life threatening interaction when taken with {v} Natalizumab
Canakinumab {u} may lead to a major life threatening interaction when taken with {v} Satralizumab
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Canakinumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Alprazolam
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Canakinumab may lead to a major life threatening interaction when taken with Natalizumab
Canakinumab may lead to a major life threatening interaction when taken with Satralizumab